Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28661608 | 0.87 | ALOX5 (0.47) | PDE9AESR1ESR2GSTP1ALOX5 | |
| SCHEMBL4895301 | 0.86 | PDE9A (0.42) | PDE9AESR1ESR2GSTP1ALOX5 | |
| SCHEMBL36279 | 0.83 | ESR1 (0.52) | PDE9AESR1ESR2GSTP1ALOX5 | |
| SCHEMBL29350362 | 0.83 | ESR1 (0.52) | PDE9AESR1ESR2GSTP1ALOX5 | |
| SCHEMBL2379728 | 0.83 | ESR1 (0.52) | PDE9AESR1ESR2GSTP1ALOX5 | |
| SCHEMBL25060858 | 0.81 | ESR1 (0.50) | PDE9AESR1ESR2GSTP1ALOX5 | |
| Methane SCHEMBL27979911 | 0.81 | ESR1 (0.50) | PDE9AESR1ESR2GSTP1ALOX5 | |
| SCHEMBL25566510 | 0.81 | ESR1 (0.50) | PDE9AESR1ESR2GSTP1ALOX5 | |
| SCHEMBL19467302 | 0.80 | HSD17B1 (0.39) | PDE9AESR1ESR2GSTP1ALOX5 | |
| SCHEMBL3867431 | 0.79 | ESR1 (0.48) | PDE9AESR1ESR2GSTP1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2860782-B1 | Semiconducting material comprising a phosphine oxide matrix and metal salt | NOVALED GMBH (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-10026902-B2 | Semiconducting material comprising a phosphine oxide matrix and metal salt | NOVALED GMBH (DE) | 2018-07-17 | — | — | US | disclosed |
| EP-3055891-A1 | SEMICONDUCTING MATERIAL COMPRISING A PHOSPHINE OXIDE MATRIX AND METAL SALT | Novaled GmbH (DE) | 2016-08-17 | — | — | EP | disclosed |
| US-20160211455-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | NOVALED GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| EP-2860782-A1 | Semiconducting material comprising a phosphine oxide matrix and metal salt | Novaled GmbH (DE) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10026902-B2 | Semiconducting material comprising a phosphine oxide matrix and metal salt | PSPH, STMN1, STMN2 | PDE9A 395/4885ESR1 2389/4885ESR2 3749/4885 |
| US-20160211455-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | PSPH, STMN1, STMN2 | PDE9A 521/4885ESR1 2012/4885ESR2 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.